Avanir Deal Partly Plugs Otsuka’s Abilify Gap
This article was originally published in PharmAsia News
While some eyebrows are being raised over the sum Otsuka Pharmaceutical is proposing to shell out for a small U.S. CNS company with only one niche marketed product, the pipeline the deal will bring is being viewed positively by some analysts.
You may also be interested in...
Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.